Barclays raised the firm’s price target on BioCryst (BCRX) to $8 from $7 and keeps an Equal Weight rating on the shares post the Q3 report. Orladeyo’s Q3 revenue was a modest beat and the company’s 2024 revenue guidance was narrowed to the upper end of tee range, the analyst tells investors in a research note.